| SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments. | SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
Chu E, Wu J, Kang SS, Kang Y., Free PMC Article | 02/7/2024 |
| Identification and elucidation of cross talk between SLAM Family Member 7 (SLAMF7) and Toll-like receptor (TLR) pathways in monocytes and macrophages. | Identification and elucidation of cross talk between SLAM Family Member 7 (SLAMF7) and Toll-like receptor (TLR) pathways in monocytes and macrophages.
Choe U, Pham Q, Kim YS, Yu L, Wang TTY., Free PMC Article | 07/12/2023 |
| SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity. | SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity.
O'Connell P, Blake MK, Godbehere S, Amalfitano A, Aldhamen YA., Free PMC Article | 10/15/2022 |
| SLAMF7 engagement superactivates macrophages in acute and chronic inflammation. | SLAMF7 engagement superactivates macrophages in acute and chronic inflammation.
Simmons DP, Nguyen HN, Gomez-Rivas E, Jeong Y, Jonsson AH, Chen AF, Lange JK, Dyer GS, Blazar P, Earp BE, Coblyn JS, Massarotti EM, Sparks JA, Todd DJ, Accelerating Medicines Partnership (AMP) RA/SLE Network, Rao DA, Kim EY, Brenner MB., Free PMC Article | 03/5/2022 |
| SLAMF7 selectively favors degranulation to promote cytotoxicity in human NK cells. | SLAMF7 selectively favors degranulation to promote cytotoxicity in human NK cells.
Gutierrez-Guerrero A, Mancilla-Herrera I, Maravillas-Montero JL, Martinez-Duncker I, Veillette A, Cruz-Munoz ME. | 02/12/2022 |
| CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. | CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
Soh KT, Tario JD Jr, Hahn T, Hillengass J, McCarthy PL, Wallace PK., Free PMC Article | 01/8/2022 |
| SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability. | SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability.
Roh SA, Kwon YH, Lee JL, Kim SK, Kim JC. | 11/22/2021 |
| Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. | Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments.
Geis M, Nowotny B, Bohn MD, Kouhestani D, Einsele H, Bumm T, Stuhler G., Free PMC Article | 07/3/2021 |
| Association of circulating SLAMF7(+)Tfh1 cells with IgG4 levels in patients with IgG4-related disease. | Association of circulating SLAMF7(+)Tfh1 cells with IgG4 levels in patients with IgG4-related disease.
Higashioka K, Ota Y, Maehara T, Moriyama M, Ayano M, Mitoma H, Akahoshi M, Arinobu Y, Horiuchi T, Nakamura S, Akashi K, Niiro H., Free PMC Article | 06/5/2021 |
| SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. | SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment.
O'Connell P, Hyslop S, Blake MK, Godbehere S, Amalfitano A, Aldhamen YA., Free PMC Article | 05/22/2021 |
| Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide. | Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.
Elmaagacli AH, Jehn C, Shikova Y, Huber M, Salwender H, Dahmash F, Singh A, Niggemann C, Vierbuchen M. | 05/8/2021 |
| SLAMF7 and IL-6R define distinct cytotoxic versus helper memory CD8(+) T cells. | SLAMF7 and IL-6R define distinct cytotoxic versus helper memory CD8(+) T cells.
Loyal L, Warth S, Jürchott K, Mölder F, Nikolaou C, Babel N, Nienen M, Durlanik S, Stark R, Kruse B, Frentsch M, Sabat R, Wolk K, Thiel A., Free PMC Article | 01/9/2021 |
| Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy. | Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.
Elmaagacli AH, Salwender H, Jehn C, Dahmash F, Singh A, Wilson O, Pannenbeckers M, Niggemann C, Vierbuchen M. | 09/12/2020 |
| The data show that the great majority of primary patient plasmablastic lymphoma (PBL) cases from a variety of subtypes express SLAMF7. From a diagnostic histopathology perspective, SLAMF7 may be a useful addition to a panel of markers for the diagnosis and characterization of PBL | SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target.
Shi J, Bodo J, Zhao X, Durkin L, Goyal T, Meyerson H, Hsi ED. | 05/9/2020 |
| immune receptor CD48 is overexpressed on MM cells together with SLAMF7, and that CD48 may be considered as an alternative target for treatment of MM in cases showing weak expression of SLAMF7. | Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma.
Ashour R, Ri M, Aly SS, Yoshida T, Tachita T, Kanamori T, Aoki S, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Komatsu H, Mansour S, Elsaied AA, Iida S. | 12/21/2019 |
| this study shows that SLAMF7 is a critical negative regulator of IFN-alpha-mediated CXCL10 production in chronic HIV infection | SLAMF7 Is a Critical Negative Regulator of IFN-α-Mediated CXCL10 Production in Chronic HIV Infection.
O'Connell P, Pepelyayeva Y, Blake MK, Hyslop S, Crawford RB, Rizzo MD, Pereira-Hicks C, Godbehere S, Dale L, Gulick P, Kaminski NE, Amalfitano A, Aldhamen YA., Free PMC Article | 11/9/2019 |
| These data provide emerging evidence that SLAMF7 could be a target of potential therapeutic intervention in carotid atherosclerosis. | Integrated DNA methylation and gene expression analysis identifies SLAMF7 as a key regulator of atherosclerosis.
Xia Z, Gu M, Jia X, Wang X, Wu C, Guo J, Zhang L, Du Y, Wang J., Free PMC Article | 10/5/2019 |
| Down-regulation of SLAMF7 and up-regulation of TREM1 occur in primary and metastatic stage IV colorectal cancer tissues. | Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
Lee JL, Roh SA, Kim CW, Kwon YH, Ha YJ, Kim SK, Kim SY, Cho DH, Kim YS, Kim JC., Free PMC Article | 05/18/2019 |
| cancer cell expression of SLAMF7 is not required for phagocytosis and, in contrast to CD47 expression, should not be used as selection criterion for CD47-targeted therapy. | Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
He Y, Bouwstra R, Wiersma VR, de Jong M, Jan Lourens H, Fehrmann R, de Bruyn M, Ammatuna E, Huls G, van Meerten T, Bremer E., Free PMC Article | 04/6/2019 |
| Memory CD8+ T cells from SLE patients displayed decreased amounts of SLAMF7, a surface receptor that characterizes effector CD8+ T cells. Ligation of SLAMF7 increased CD8+ T cell degranulation capacity and the percentage of IFNgamma-producing cells in response to antigen challenge in SLE patients and healthy controls. SLAMF7 engagement promoted cytotoxic lysis of target cells in response to stimulation with viral antig... | Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus.
Comte D, Karampetsou MP, Yoshida N, Kis-Toth K, Kyttaris VC, Tsokos GC., Free PMC Article | 08/19/2017 |
| phagocytosis of haematopoietic tumour cells during SIRPalpha-CD47 blockade was strictly dependent on SLAM family receptors in vitro and in vivo; in both mouse and human cells, this function required a single SLAM family member, SLAMF7 (also known as CRACC, CS1, CD319), expressed on macrophages and tumour cell targets | SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Chen J, Zhong MC, Guo H, Davidson D, Mishel S, Lu Y, Rhee I, Pérez-Quintero LA, Zhang S, Cruz-Munoz ME, Wu N, Vinh DC, Sinha M, Calderon V, Lowell CA, Danska JS, Veillette A., Free PMC Article | 08/19/2017 |
| Cohort statistics revealed a significant increase of circulating sSLAMF7 in multiple myeloma patients versus normal controls | Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.
Postelnek J, Neely RJ, Robbins MD, Gleason CR, Peterson JE, Piccoli SP. | 02/18/2017 |
| Blimp-1 regulates the transcription of CS1 gene in NK and B cell lines from multiple myeloma and diffuse large B cell lymphoma patients. | Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.
Kim JR, Mathew SO, Mathew PA. | 08/20/2016 |
| SLAMF7-triggered inhibition is mediated by a mechanism involving Src kinases, CD45, and SHIP-1 that is defective in MM cells | Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.
Guo H, Cruz-Munoz ME, Wu N, Robbins M, Veillette A., Free PMC Article | 02/14/2015 |
| Our data highlight the therapeutic potential of targeting CD319 in rheumatoid arthritis | PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis.
Woo J, Vierboom MP, Kwon H, Chao D, Ye S, Li J, Lin K, Tang I, Belmar NA, Hartman T, Breedveld E, Vexler V, 't Hart BA, Law DA, Starling GC., Free PMC Article | 11/8/2014 |